The market for radioligand therapies is expected to grow significantly in the coming years. This is due to the increasing number of patients who are being diagnosed with cancer, the growing awareness of radioligand therapies, the increasing number of radioligand therapies that are under clinical trials, and the increasing interest of major pharmaceutical companies toward it.
LAS VEGAS, July 9, 2024 /PRNewswire/ -- DelveInsight's Radioligand Therapies Market Insights report includes a comprehensive understanding of current treatment practices, emerging radioligand therapies, market share of individual therapies, and current and forecasted Radioligand Therapies market size from 2020 to 2034, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the Radioligand Therapies Market Report
- As per DelveInsight's analysis, the radioligand therapies market is anticipated to grow at a significant CAGR by 2034.
- Leading radioligand therapy companies such as Curium US, Eli Lilly, Point Biopharma, Fusion, Astrazeneca, Endocyte, Progenics Pharmaceuticals, Inc., AdvanCell Isotopes Pty Limited, and others are developing novel radioligand therapies that can be available in the radioligand therapies market in the coming years.
- Some of the key radioligand therapies include 177Lu-PSMA-I&T, Lu-PNT2002, FPI-2265, 225^Ac-PSMA-617, I-131-1095, [212Pb]Pb-ADVC001, and others.
- In March 2024, Novartis announced that it had acquired Mariana Oncology, a biotech specializing in developing radioligand therapies (RLTs) for cancer treatment. As per terms of the agreement, Novartis is expected to make an upfront payment of $1 billion, with further potential payments of up to $750 million upon the completion of pre-specified milestones.
- In March 2024, AstraZeneca announced that it will acquire Fusion Pharmaceuticals for USD 2 billion to accelerate the development of next-generation radioconjugates to treat cancer. The acquisition brings new expertise and pioneering R&D, manufacturing, and supply chain capabilities in actinium-based RCs to AstraZeneca
- In January 2024, the FDA approved Novartis's new automated radioligand therapy production plant for PLUVICTO-a radioligand therapy (RLT) for prostate cancer.
- In January 2024, InHealth launched the United Kingdom's first relocatable radioligand therapy service.
- In October 2023, Lilly acquired Point Biopharma with USD 1.4 billion and deepened its oncology pipeline. In the deal, Lilly will gain ownership of Point's lead asset PNT2002, a radioligand therapy against targeting the prostate-specific membrane antigen (PSMA), being trialed for patients with metastatic castration-resistant prostate cancer who had progressed after hormonal treatment. The candidate carries the beta-emitting radioisotope lutetium-177.
Discover which therapies are expected to grab the radioligand therapies market share @ Radioligand Therapies Market Report
Radioligand Therapies Market Dynamics
The radioligand therapies market has witnessed significant dynamics driven by advancements in oncology and nuclear medicine. One of the key drivers of market growth is the increasing incidence of cancer worldwide. As cancer rates rise, there is a growing demand for effective therapies that can improve patient outcomes and quality of life. Radioligand therapies, such as those targeting prostate-specific membrane antigen (PSMA) for prostate cancer or somatostatin receptors for neuroendocrine tumors, have shown promising results in clinical trials, fueling their adoption in clinical practice.
Moreover, technological advancements in imaging and radiopharmaceutical production have bolstered the development and commercialization of radioligand therapies. The integration of positron emission tomography (PET) and single-photon emission computed tomography (SPECT) imaging has enhanced the diagnosis and staging of cancers, facilitating the selection of appropriate patients for radioligand therapy.
Market dynamics also include regulatory approvals and reimbursement policies, which play a critical role in the adoption and accessibility of radioligand therapies. Regulatory agencies worldwide are increasingly recognizing the potential of these therapies, expediting their approval processes for various cancer types. Furthermore, efforts to streamline reimbursement pathways are essential in ensuring that patients can afford these innovative treatments.
Looking forward, collaborations between pharmaceutical companies, academic institutions, and healthcare providers are expected to drive further advancements in radioligand therapies. These partnerships facilitate research and development initiatives, clinical trials, and the establishment of treatment guidelines, ultimately expanding the therapeutic landscape for cancer patients globally. As the field continues to evolve, ongoing research into novel targets and isotopes promises to unlock new opportunities for personalized and effective cancer treatment strategies.
Radioligand Therapies Treatment Market
Radioligand therapies are a burgeoning treatment modality for diverse cancers. They demonstrate efficacy in enhancing progression-free survival and quality of life for neuroendocrine tumors, and in improving overall survival for metastatic castration-resistant prostate cancer, prompting their inclusion in cancer care guidelines. Moreover, RLT holds promise for treating aggressive or rare cancers, especially metastatic cases lacking effective therapies.
Several RLTs, including LUTATHERA, PLUVICTO, XOFIGO, and ZEVALIN, are FDA-approved. LUTATHERA represents a significant breakthrough as the inaugural treatment sanctioned specifically for pediatric patients diagnosed with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). This approval signals a new prospect for young individuals grappling with this uncommon form of cancer. Moreover, LUTATHERA has also been endorsed in Europe for adults with unresectable or metastatic, progressive, well-differentiated (G1 and G2), SSTR-positive GEP-NETs, and in Japan for SSTR-positive NETs.
LUTATHERA is a radioactive medication designed to target somatostatin receptors found on certain tumor cells. By binding to these receptors and entering the cells, the drug delivers radiation that can effectively damage the tumor cells.
PLUVICTO represents the first FDA-approved targeted radioligand therapy for eligible patients suffering from mCRPC, integrating a targeting molecule (ligand) with a therapeutic radioisotope. The active component of lutetium Lu 177 vipivotide tetraxetan is the radionuclide lutetium-177, which is coupled with a moiety that binds to PSMA, a transmembrane protein expressed in prostate cancer, including mCRPC. Once lutetium Lu 177 vipivotide tetraxetan attaches to PSMA-expressing cells, the beta-minus emissions from lutetium-177 deliver radiation to both PSMA-expressing cells and neighboring cells, inducing DNA damage that may result in cell death. PLUVICTO achieved sales exceeding USD 950 million.
NOVARTIS currently offers two RLTs globally, with multiple others in development and over 15 clinical trials underway or planned. The sector has seen acquisitions, such as AstraZeneca's acquisition of Fusion Pharmaceutical, advancing its RLT FPI-2265 into phase II/III clinical trials.
Learn more about the FDA-approved radioligand therapies @ Radioligand Therapies Drugs
Key Emerging Radioligand Therapies and Companies
Several key players, including AstraZeneca/Fusion (FPI-2265), Eli Lilly (Lu-PNT2002), Curium (177Lu-PSMA-I&T), and others, are involved in developing drugs for radioligand therapies for various indications such as prostate cancer, pancreatic cancer, and others.
177Lu-PSMA-I&T targets prostate-specific membrane antigen, found in over 85% of prostate cancer cells. Due to its high specificity for this antigen, the radioisotope selectively targets these cancer cells. Upon binding to the cancer cell, the radioisotope is taken up internally, where its radioactive properties disrupt the cancer cell's DNA strands, effectively killing it.
Lantheus Holdings holds exclusive global commercialization rights (excluding specific Asian territories) for 177Lu-PNT2002, a potential radioligand therapy utilizing PSMA-targeted ligand PSMA-I&T paired with the beta-emitting radioisotope no-carrier-added lutetium-177. The therapy, developed by POINT, gained Fast Track designation from the FDA in April 2023 for treating mCRPC.
Other radioligand therapies in the pipeline include
- FPI-2265: AstraZeneca/Fusion
- 225^Ac-PSMA-617: Endocyte
- I-131-1095: Progenics Pharmaceuticals, Inc.
- [212Pb]Pb-ADVC001: AdvanCell Isotopes Pty Limited
The anticipated launch of these emerging therapies are poised to transform the radioligand therapies market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the Radioligand Therapies market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
To know more about radioligand therapies clinical trials, visit @ Radioligand Therapies Treatment Drugs
Radioligand Therapies Overview
Radioligand therapies (RLT) represent a specialized form of targeted nuclear medicine designed to detect and treat diseases like cancer. These therapies deliver radiation specifically to cancer cells that exhibit particular targets. RLT marks a significant stride in precision oncology, providing a focused approach to combating cancer.
RLT involves two main components: a radioisotope and a cell-targeting compound (ligand), chemically linked together. The radioisotope emits radiation that targets and destroys specific cancer cells, while the ligand attaches to cells expressing these specific targets, guiding the radioisotope to its intended destination.
Therapeutic radioisotopes are typically produced in dedicated nuclear reactors or generators, and then transported to production facilities where they are combined with the cell-targeting compound. The final product is packaged in vials, undergoes rigorous quality testing, is secured in special lead-shielded containers, and finally shipped directly to hospitals or clinics as a ready-to-administer therapy.
Radioligand Therapies Report Metrics | Details |
Study Period | 2020-2034 |
Radioligand Therapies Report Coverage | 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
Key Radioligand Therapies Companies | Curium US, Eli Lilly, Point Biopharma, Fusion, Astrazeneca, Endocyte, Progenics Pharmaceuticals, Inc., AdvanCell Isotopes Pty Limited, and others |
Key Radioligand Therapies | 177Lu-PSMA-I&T, Lu-PNT2002, FPI-2265, 225^Ac-PSMA-617, I-131-1095, [212Pb]Pb-ADVC001, and others |
Scope of the Radioligand Therapies Market Report
- Radioligand Therapies Therapeutic Assessment: Radioligand Therapies current marketed and emerging therapies
- Radioligand Therapies Market Dynamics: Attribute Analysis of Emerging Radioligand Therapies Drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL's views, Analyst's views, Radioligand Therapies Market Access and Reimbursement
Discover more about radioligand therapies in development @ Radioligand Therapies Clinical Trials
Table of Contents
1. | Radioligand Therapies Market Key Insights |
2. | Radioligand Therapies Market Report Introduction |
3. | Radioligand Therapies Market Overview at a Glance |
4. | Radioligand Therapies Market Executive Summary |
5. | Disease Background and Overview |
6. | Radioligand Therapies Treatment and Management |
7. | Radioligand Therapies Epidemiology and Patient Population |
8. | Patient Journey |
9. | Radioligand Therapies Marketed Drugs |
10. | Radioligand Therapies Emerging Drugs |
11. | Seven Major Radioligand Therapies Market Analysis |
12. | Radioligand Therapies Market Outlook |
13. | Potential of Current and Emerging Therapies |
14. | KOL Views |
15. | Unmet Needs |
16. | SWOT Analysis |
17. | Appendix |
18. | DelveInsight Capabilities |
19. | Disclaimer |
20. | About DelveInsight |
Related Reports
Nuclear Medicine Market
Nuclear Medicine Market Insight, Competitive Landscape, and Market Forecast - 2030 report delivers an in-depth understanding of market trends, market drivers, market barriers, and key nuclear medicine companies, including Lantheus., Cardinal Health., GE Healthcare, Curium Pharma, Nihon Medi-Physics Co., Ltd., Novartis (Advanced Accelerator Applications), Cambridge Isotope Laboratories, Inc, Sotera Health LLC, Bracco Imaging SpA, Jubilant Pharma Limited, Necsa, IBA Radiopharma Solutions, Bayer AG, Norgine, Eczacibasi-Monrol, NorthStar Medical Radioisotopes, LLC., Eckert & Ziegler., Telix Pharmaceuticals Limited, ITM Isotope Technologies Munich SE, Mallinckrodt PLC, among others.
Gastroenteropancreatic Neuroendocrine Tumors Market
Gastroenteropancreatic Neuroendocrine Tumors Market Insights, Epidemiology, and Market Forecast - 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key GEP-NETs companies including Eli Lilly and Company, Phanes Therapeutics, Novatek Pharmaceuticals, Camurus AB, Advanced Accelerator Applications, RayzeBio, Inc., Aadi Bioscience, Inc., PharmaMar, among others.
Neuroendocrine Tumors Market
Neuroendocrine Tumors Market Insights, Epidemiology, and Market Forecast - 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key neuroendocrine tumors companies including Radiomedix, Inc, Orano Med LLC, Molecular Targeting Technologies, Inc., Viewpoint Molecular Targeting, Exelixis, Eli Lilly and Company, Teclison Ltd., Novatek Pharmaceuticals, Phanes Therapeutics, Camurus AB, Hutchmed, Merck Sharp & Dohme LLC, BioXcel Therapeutics Inc, Boehringer Ingelheim, RayzeBio, Inc., Vyriad, Inc., Hoffmann-La Roche, Monte Rosa Therapeutics, Inc, Amgen, ORIC Pharmaceuticals, among others.
Neuroendocrine Tumors Pipeline
Neuroendocrine Tumors Pipeline Insight - 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key neuroendocrine tumors companies, including Jiangsu Hengrui Medicine, MedImmune, Genentech, Merck & Co, Pfizer, Takeda Oncology, Hutchison MediPharma, Provectus Biopharmaceuticals, NanoValent Pharmaceuticals, Camurus, ITM Solucin, Pfizer, Radiomedix, Inc., Orano Med LLC, Clarity Pharmaceuticals, TaiRx, Peloton Therapeutics, RayzeBio, Ascentage Pharma, Debiopharm, Boehringer Ingelheim, Roche, Ipsen, Medelis Inc., Exelixis, EpicentRx, Inc., Tarveda Therapeutics, Teclison Ltd., Novatek Pharmaceuticals, Phanes Therapeutics, Fujifilm Pharmaceuticals, Jazz Pharmaceuticals, 23andMe, Inc., Celgene, Crinetics Pharmaceuticals Inc., POINT Biopharma, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact Us
Shruti Thakur
info@delveinsight.com
+14699457679
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/radioligand-therapies-market-to-show-immense-growth-by-2034-predicts-delveinsight--key-companies---curium-us-eli-lilly-point-biopharma-fusion-astrazeneca-302191578.html
